
For the year ended Mar 2019, Sun Pharma Advanced Research Company reported revenue of ₹183 crore and net profit of -₹145 crore, against ₹77 crore and -₹312 crore a year earlier.
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183 | 77 | 253 | 137 | 239 | 76 | 72 | 39 | 1,909 |
| Expenses | 334 | 387 | 388 | 324 | 451 | 475 | 393 | -1,570 | 293 |
| Operating profit | -151 | -310 | -135 | -187 | -212 | -399 | -322 | 1,609 | 1,617 |
| Operating margin % | -83% | -404% | -53% | -136% | -89% | -528% | -448% | 4,110% | 85% |
| Other income | 14 | 10 | 5 | 7 | 9 | 26 | 0 | -14 | 13 |
| Interest | 0 | 3 | 11 | 13 | 8 | 1 | 9 | 32 | 36 |
| Depreciation | 8 | 9 | 11 | 10 | 12 | 13 | 12 | 10 | 10 |
| Profit before tax | -145 | -312 | -151 | -203 | -223 | -387 | -343 | 1,553 | 1,584 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net profit | -145 | -312 | -151 | -203 | -223 | -387 | -343 | 1,553 | 1,584 |
| EPS (₹) | -4.48 | -9.63 | -4.66 | -6.27 | -6.86 | -11.93 | -10.55 | 47.86 | 48.82 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
For the financial year ended Mar 2019, Sun Pharma Advanced Research Company's revenue was ₹183 crore and net profit -₹145 crore; net profit rose 53.53% from -₹312 crore in Mar 2020.
From Mar 2022 to Mar 2019, Sun Pharma Advanced Research Company's revenue grew at a compound annual rate of 10.1%. Past growth does not indicate future results.
Annual EPS for Mar 2019 was -₹4.48.
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Track SPARC live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.